Rolling out its Oyavas (bevacizumab) biosimilar to Roche’s Avastin in Europe, alongside launching complex generics such as Jevtana (cabazitaxel) and Faslodex (fulvestrant), helped bring about 9% sales growth to €638.7m ($701.7m) for STADA Arzneimittel AG’s newly-organized Specialty segment in 2021.
Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings
Stada Enjoys 8% Top Line Growth In 2021 But Adjusted EBITDA Dips By 1%
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
